Glycogen Storage Disease Type II Clinical Trial
Official title:
A French Multicenter Open Label Phase 4 Extension Study of Long-term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Alfa Development Studies in France
This long-term open label safety and efficacy study is intended to follow up, and to provide post-trial access to enzyme replacement therapy (ERT) with avalglucosidase alfa to patients with Pompe disease in France who have completed Study EFC14028, LTS13769, or ACT14132, from market authorization until reimbursement of avalglucosidase alfa in France or until December 2024, whichever comes first. - Study visit frequency: every 2 weeks
Treatment duration approximately 2 years and 6 months: until reimbursement of avalglucosidase alfa in France or until December 2024, whichever comes first ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00231400 -
Pompe Disease Registry Protocol
|
||
Recruiting |
NCT04910776 -
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
|
Phase 3 | |
Not yet recruiting |
NCT05017402 -
Higher Dose of Alglucosidase Alpha for Pompe Disease
|
||
Withdrawn |
NCT01656590 -
High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease
|
Phase 2 | |
Completed |
NCT00701129 -
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
|
Phase 4 | |
Active, not recruiting |
NCT04093349 -
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
|
Phase 1/Phase 2 | |
Completed |
NCT02363153 -
Diet and Exercise in Pompe Disease
|
N/A | |
Completed |
NCT00074932 -
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease
|
N/A | |
Completed |
NCT00025896 -
Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease
|
Phase 2 | |
Completed |
NCT00001331 -
Genetic and Family Studies of Inherited Muscle Diseases
|
N/A | |
Completed |
NCT00077662 -
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease
|
N/A | |
Recruiting |
NCT05951790 -
Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease
|
N/A | |
Completed |
NCT00125879 -
Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602
|
Phase 2/Phase 3 | |
Recruiting |
NCT04848779 -
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
|
||
Recruiting |
NCT02761421 -
Effect of Motor Development, Motor Function and Electrophysiologic Findings of IOPD Under ERT
|
N/A | |
Active, not recruiting |
NCT02635269 -
Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy
|
N/A | |
Completed |
NCT00051935 -
A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II
|
Phase 2 | |
Completed |
NCT00053573 -
rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)
|
Phase 1/Phase 2 | |
Completed |
NCT02801539 -
Respiratory Muscle Training in L-Onset Pompe Disease (LOPD)
|
N/A | |
Completed |
NCT03687333 -
Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment
|
Phase 4 |